Cost-effectiveness of the 21-gene recurrence score assay in the setting of multifactorial decision making for chemotherapy in early-stage breast cancer.
Reed S, Dinan M, Schulman K, Lyman G. Cost-effectiveness of the 21-gene recurrence score assay in the setting of multifactorial decision making for chemotherapy in early-stage breast cancer. Journal Of Clinical Oncology 2012, 30: 1525-1525. DOI: 10.1200/jco.2012.30.15_suppl.1525.Peer-Reviewed Original ResearchIncremental cost-effectiveness ratioEstrogen receptor-positive breast cancerReceptor-positive breast cancerUse of chemotherapyRecurrence scoreBreast cancerRisk groupsEarly-stage breast cancerPatient time costsDirect medical costsLifetime direct medical costsQuality-adjusted survivalCost-effectiveness ratioHealthcare system perspectiveLower indirect costsMultifactorial decisionDecision analytic modelProbabilistic sensitivity analysesCost-effectiveness estimatesDistant recurrenceHormonal therapyClinicopathologic characteristicsDisease recurrenceAttributable costsMedical costs